Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Assets Average (2016 - 2025)

Celldex Therapeutics (CLDX) has 15 years of Assets Average data on record, last reported at $615.7 million in Q4 2025.

  • For Q4 2025, Assets Average fell 23.78% year-over-year to $615.7 million; the TTM value through Dec 2025 reached $615.7 million, down 23.78%, while the annual FY2025 figure was $687.7 million, 9.33% up from the prior year.
  • Assets Average reached $615.7 million in Q4 2025 per CLDX's latest filing, down from $670.4 million in the prior quarter.
  • Across five years, Assets Average topped out at $857.2 million in Q2 2024 and bottomed at $211.8 million in Q2 2021.
  • Average Assets Average over 5 years is $503.3 million, with a median of $423.9 million recorded in 2022.
  • Peak YoY movement for Assets Average: fell 24.94% in 2023, then surged 187.93% in 2024.
  • A 5-year view of Assets Average shows it stood at $452.4 million in 2021, then dropped by 20.21% to $361.0 million in 2022, then grew by 3.31% to $372.9 million in 2023, then skyrocketed by 116.59% to $807.8 million in 2024, then fell by 23.78% to $615.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $615.7 million in Q4 2025, $670.4 million in Q3 2025, and $715.9 million in Q2 2025.